Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 4/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18639389 | 0.80 | LMNA (0.46) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL25412507 | 0.78 | LMNA (0.43) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL23933137 | 0.76 | USP2 (0.39) | SMN1; SMN2HPGD | |
| SCHEMBL5500990 | 0.76 | LMNA (0.56) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL14880138 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL8821262 | 0.75 | LMNA (0.51) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL12468367 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL12468857 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL16230841 | 0.73 | LMNA (0.56) | SMN1; SMN2LMNAPOLBALDH1A1HPGD | |
| SCHEMBL30002152 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885POLB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.